Introduction
Canagliflozin, of the Sodium Glucose Co-Transporter 2 (SGLT-2) inhibitors class of oral hypoglycaemic agents, is used in the treatment of Type 2 Diabetes Mellitus (T2DM). SGLT-2 inhibitors work by lowering the renal threshold for glucose excretion, resulting in a greater urinary excretion of glucose. Canagliflozin was approved for use in both the EU and USA in 2013. In the UK, the National Institute for Health and Care Excellence (NICE) state that it can be used as the first stage of treatment intensification in T2DM 1 , following use of metformin.
In May 2015, the FDA published a safety warning 2 for SGLT-2 inhibitors, reporting over twenty cases of diabetic ketoacidosis (DKA) in patients taking the medication. We report the case of a 43-year-old Caucasian male who presented to A&E four months following initiation of treatment with canagliflozin.
The Case
The patient was a 43-year-old Caucasian male with T2DM. His blood glucose levels were previously well controlled with metformin, sitagliptin, gliclazide and canagliflozin. His BMI was 21.8. He was haemodynamically stable at presentation, and throughout his admission.
Symptoms:
• Three days of fatigue, loss of appetite, and generalised aches and pains • One episode of vomiting on the day of presentation • Several episodes of diarrhoea four days earlier, with severe right-sided abdominal pain on the day of presentation. He also reported symptoms that were in keeping with ileus.
Clinical Case: ePoster
Discussion
To our knowledge this is the first reported case in the UK of a patient presenting with euglycaemic DKA caused by treatment with SGLT-2 inhibitors.
Cases of euglycaemic diabetic ketoacidosis (euDKA) have been reported in patients taking canagliflozin 3, 4 . Increased urinary excretion of glucose lowers plasma glucose levels, and predisposes the patient to a ketogenic state. Since blood glucose levels are within range, and unless patients monitor ketone levels, they may not seek medical attention despite feeling profoundly unwell. Predisposing factors are thought to include acute illness, dehydration, periods of fasting, and relative insulinopaenia 5 .
It is important for both clinicians and patients to be aware of the risk of euDKA when taking SGLT-2 inhibitors, as acidosis may develop insidiously. Provision of ketone-meters to patients prescribed this class of medication may prevent development of euDKA, or lead to earlier admissions to hospital. This warrants further research. Patients should be educated about the risks of taking an SGLT-2 inhibitor, and the possibility that they may become unwell while still having an acceptable plasma glucose. 
